Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29795957 | 1.00 | LMNA (0.49) | LMNASMN1; SMN2KDM4EALDH1A1CDK1 | |
| SCHEMBL29739612 | 0.85 | CTSB (0.57) | LMNASMN1; SMN2KDM4EALDH1A1POLB | |
| SCHEMBL23213590 | 0.85 | CTSB (0.57) | LMNASMN1; SMN2KDM4EALDH1A1POLB | |
| SCHEMBL4362133 | 0.82 | LMNA (0.71) | LMNASMN1; SMN2KDM4EALDH1A1CDK1 | |
| SCHEMBL589105 | 0.82 | ALDH1A1 (0.57) | LMNASMN1; SMN2KDM4EALDH1A1CDK1 | |
| SCHEMBL29795985 | 0.81 | LMNA (0.51) | LMNASMN1; SMN2KDM4EALDH1A1ACHE | |
| SCHEMBL23213367 | 0.81 | LMNA (0.51) | LMNASMN1; SMN2KDM4EALDH1A1ACHE | |
| SCHEMBL27290060 | 0.78 | ALDH1A1 (0.50) | LMNASMN1; SMN2KDM4EALDH1A1POLB | |
| SCHEMBL17979918 | 0.78 | LMNA (0.51) | LMNASMN1; SMN2KDM4EALDH1A1CDK1 | |
| SCHEMBL29796153 | 0.78 | ALDH1A1 (0.47) | LMNASMN1; SMN2KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| CN-117917402-A | Isoindolylamide compound, and pharmaceutical composition and application thereof | 暨南大学 | 2024-04-23 | — | — | CN | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-08-04 | — | — | US | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | LMNA 395/4885SMN1; SMN2 187/4885KDM4E 3979/4885 |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | AOC2, AOC3, INF2 | LMNA 1379/4885SMN1; SMN2 2675/4885KDM4E 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.